- Psyence BioMed (PBM, Financial) invests USD $500,000 in PsyLabs to advance psychedelic medicine development.
- PBM secures exclusive rights for pharmaceutical-grade Ibogaine supply.
- Partnership targets Substance Use Disorders (SUD) and Alcohol Use Disorder (AUD).
Psyence BioMed Inc. (PBM) has announced a strategic follow-on investment of USD $500,000 into PsyLabs, a move that strengthens their collaboration in the burgeoning field of psychedelic medicine development. This investment follows their agreement from September 2024, where PBM acquired an 11.13% equity stake in the privately-held PsyLabs, which specializes in the production of psychedelic active pharmaceutical ingredients (APIs).
The investment comprises two key components: an exclusive, royalty-bearing IP licensing agreement for the supply of pharmaceutical-grade, EU-GMP compliant, nature-derived psilocybin, and an exclusive right of first refusal for the worldwide supply of pharmaceutical-grade, nature-derived Ibogaine. These agreements aim to bolster PBM's pipeline in treating Substance Use Disorders (SUD), including Alcohol Use Disorder (AUD).
Psyence BioMed's strategy aims to create a diversified pipeline of psychedelic-based therapeutics, enhancing supply chain security and therapeutic development capabilities. This initiative is a part of their broader vision to become a leading, vertically integrated psychedelic biotech company. PsyLabs will supply PBM with high-quality psychedelic compounds, supporting clinical trials and therapeutic development efforts. The agreement remains subject to definitive terms and regulatory approvals.
Dr. Neil Maresky, CEO of Psyence BioMed, emphasized the potential of Ibogaine as a novel therapeutic avenue, highlighting its promise in addressing challenging mental health conditions. The partnership reflects a shared vision of advancing the science and development of nature-derived psychedelic medicines, capitalizing on the unique properties of these compounds to offer new treatment solutions.
